Pirouette Pharma
- Company typePrivate
- Founded2017
- HeadquartersPortsmouth, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Pirouette Pharma firmographics
Firmographics- Name
- Pirouette Pharma
- Legal name
- Pirouette Pharma Inc.
- Website
- https://pirouettepharma.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Pirouette Pharma industry classification
Industry- Product category
- Auto-Injector Drug Delivery Devices
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Auto-Injectors (Disposable & Reusable) (HLAHAIAB)
- akta.pro secondary industries
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
Keywords
Where Pirouette Pharma is headquartered
LocationHeadquarters
- HQ city
- Portsmouth
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Pirouette Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Licensing and Co-development Partnerships: Partner-ready platform enabling co-development with pharmaceutical companies to place novel and established injectables into the OnePush device. Revenue generated through licensing deals, development partnerships, and royalties from pharmaceutical companies seeking device-driven differentiation.
- Product Sales (Naloxone, Epinephrine, Promethazine, Methotrexate): Pirouette is advancing multiple mid-term block-buster potential clinical programs and near-term out-licensing assets across naloxone, epinephrine, promethazine, and methotrexate families of auto-injectors. Revenue anticipated from product sales upon FDA approval.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Pirouette Pharma product offering
Product offeringCore offering
Pirouette Pharma develops the OnePush auto-injector platform, a disc-shaped, push-button device with a fully automatic, hidden needle and smooth, controlled insertion engineered to reduce needle sensation during self-injection. The company pairs this device with reformulated injectable medicines for chronic and emergency therapies (naloxone, epinephrine, promethazine, and methotrexate families) using FDA 505(b)(2) and 351(k) abbreviated regulatory pathways. Pirouette operates both proprietary drug-device combination product programs and a partner-ready licensing model for pharmaceutical co-development.
Product overview
Pirouette Pharma offers the OnePush platform as its core product—a disc-shaped, push-button auto-injector with a fully automatic, hidden needle and controlled insertion mechanism designed to reduce needle anxiety and improve patient adherence. The company is developing multiple investigational auto-injector products using FDA 505(b)(2) and 351(k) pathways, including naloxone, epinephrine, promethazine, and methotrexate auto-injectors, targeting chronic conditions, rescue care, and military/first responder applications. The platform is API-agnostic and partner-ready for co-development with pharmaceutical companies.
Differentiator
Problem solved
Functional benefit
Brands
- OnePush: A disc-shaped, push-button auto-injector with a fully automatic, hidden needle designed to reduce needle sensation and hesitation during home use for chronic conditions such as oncology therapies and HIV medications.
Products and services
- OnePush Auto-Injector Platform Disc-shaped, push-button auto-injector with a fully automatic, hidden needle and smooth, controlled insertion engineered to reduce needle sensation and hesitation during home use. The API-agnostic, partner-ready platform enables co-development with pharmaceutical companies to place novel and established injectables for chronic conditions such as oncology therapies and HIV medications into a preferred device experience.
- Naloxone Auto-Injector Investigational naloxone auto-injector configured for layperson and first-responder use, with fixed, prefilled dosing designed to support rapid community overdose reversal workflows. Targets opioid emergency response for first responders, military personnel, and community/public health deployments.
- Epinephrine Auto-Injector Auto-injector product candidate in development within the near-term licensing pipeline for emergency-use injectable therapies. Part of the OnePush platform's out-licensing asset family.
- Promethazine Auto-Injector Auto-injector product candidate in development within the near-term licensing pipeline for injectable medicine delivery. Part of the OnePush platform's out-licensing asset family.
- Methotrexate Auto-Injector Auto-injector product candidate in development within the near-term licensing pipeline for chronic disease management therapies. Part of the OnePush platform's out-licensing asset family.
Quantifiable outcome
- 93% of patients and 88% of prescribers would switch to OnePush experience based on ease-of-use and confidence
- +3 more outcomes
Companies that use Pirouette Pharma
Customer profileSegments4 records
Ideal customer profiles2 records
Pirouette Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Pirouette Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered supporting.
- MilliporeSigmasupportingPresented at MilliporeSigma facility in February 2026, indicating collaboration on manufacturing and platform development.
- NIH SEEDsupportingFeatured on the NIH Innovation Zone stage at BIO International 2024 for safer, easier auto-injections. NIH SEED supports innovative healthcare technologies through their innovation ecosystem.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Pirouette Pharma competitors and assessment
Company assessmentBroad incumbents
- Gerresheimer: Gerresheimer manufactures primary packaging, drug delivery devices including auto-injectors, and prefillable syringes for pharma partners. Comparable device platform and pharma partner model but operates as a much larger diversified packaging and delivery supplier.
- Becton, Dickinson and Company (BD): BD offers a portfolio of drug delivery devices including auto-injectors for pharmaceutical partners across multiple therapeutic areas. Comparable in auto-injector category but as a much broader medical technology incumbent with deep channel relationships.
- West Pharmaceutical Services: West supplies drug delivery components including auto-injector platforms (e.g., SmartDose) to large pharma companies. Comparable in device technology and partner model, but operates as a much broader components and containment supplier rather than a niche platform owner.
Direct peers
- Enable Injections: Enable Injections develops wearable and large-volume injectors designed to improve patient comfort for injectable biologics and chronic therapies. Comparable patient-experience-focused injection platform targeting chronic-condition self-administration.
- Antares Pharma (Halozyme): Antares Pharma, now part of Halozyme, develops partner-ready auto-injector and pen injector platforms used by pharma companies to deliver injectable therapies. Highly comparable to Pirouette's API-agnostic, partner-ready OnePush platform and licensing revenue model.
- SHL Medical: SHL Medical is one of the largest independent developers and manufacturers of auto-injectors, supplying pharma partners globally. Directly comparable device category, partner model, and focus on patient-friendly self-injection devices.
- Ypsomed: Ypsomed develops and manufactures custom and platform auto-injectors and pen injectors sold to pharma partners for self-injection therapies. Directly comparable auto-injector platform business with partner-led commercialization model.
- kaleo (Auvi-Q): kaleo markets the Auvi-Q epinephrine auto-injector and other patient-friendly rescue injectors. Directly competes with Pirouette's epinephrine auto-injector pipeline in the same emergency-use category with similar patient-experience positioning.
- Owen Mumford: Owen Mumford designs and manufactures auto-injectors and pen injectors for pharmaceutical and consumer health partners. Comparable device category and partner business model targeting chronic and emergency injectable therapies.
Emerging players
- Emergent BioSolutions: Emergent BioSolutions markets NARCAN nasal spray for opioid overdose reversal and has historically been a major player in naloxone emergency-use products. Comparable in target therapy area (naloxone rescue) and emergency-use positioning even though the delivery modality differs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Pirouette Pharma social profiles
Digital presencePirouette Pharma compliance and trust
Trust signalCompliance3 records
Pirouette Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pirouette Pharma leadership team
Management profileNumber of profiles
Profiles9 records
Pirouette Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pirouette Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pirouette Pharma
What does Pirouette Pharma do?
Pirouette Pharma develops the OnePush auto-injector platform, a disc-shaped, push-button device with a fully automatic, hidden needle and smooth, controlled insertion engineered to reduce needle sensation during self-injection. The company pairs this device with reformulated injectable medicines for chronic and emergency therapies (naloxone, epinephrine, promethazine, and methotrexate families) using FDA 505(b)(2) and 351(k) abbreviated regulatory pathways. Pirouette operates both proprietary drug-device combination product programs and a partner-ready licensing model for pharmaceutical co-development.
Is Pirouette Pharma a public or private company?
Pirouette Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Pirouette Pharma founded?
Pirouette Pharma was founded in 2017. It employs 11 to 50 people.
Where is Pirouette Pharma based?
Pirouette Pharma is headquartered in Portsmouth, United States, in the North America region.
How does Pirouette Pharma make money?
Two revenue lines are on record. Licensing and Co-development Partnerships are the primary driver. The others are product Sales (Naloxone, Epinephrine, Promethazine, Methotrexate).
Who are Pirouette Pharma's main competitors?
Broad incumbents on record are Gerresheimer, Becton, Dickinson and Company (BD) and West Pharmaceutical Services. Direct peers are Enable Injections, Antares Pharma (Halozyme), SHL Medical, Ypsomed, kaleo (Auvi-Q) and Owen Mumford. Emergent BioSolutions is listed as an emerging player.
Does Pirouette Pharma have an API?
No public API is recorded for Pirouette Pharma.
What industry is Pirouette Pharma in?
Pirouette Pharma's product category is Auto-Injector Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAB, Auto-Injectors (Disposable & Reusable), with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 325412 and its SIC code is 3841.